OR "Angiomyofibroblastoma of the vulva with sarcomatous transformation".

**Results** A total of 69 reported cases were found. In our knowledge, the case presented is the first report of AMFB in Colombia. The age of the patients ranged between 16 and 82 years, with an average of 43 years. The main presenting symptom was the presence of a non-painful vulvar mass, although some of the patients in the reported cases reported pain and dyspareunia (8/69). The evolution time varied between 1 month and 9 years with an average of 21 months, and the size between 1 and 37 centimeters with an average of 7 centimeters. Of the cases taken to immunohistochemical study, 86% were positive for estrogen receptors and 80% for progesterone receptors, 88% were positive for desmin and 98% for vimentin, 92% were negative for S100 and the cases that were positive corresponded to the lipomatous variant, 43% were positive for α-SMA and 34% for CD 34. Definitive diagnosis is based on histological findings. In this reviewed cases, only one relapse was reported. The universal treatment is excision and only one case of relapse was reported, which corresponded to the only reported case of malignant transformation.

**Conclusion** Vulvar AMFB is a rare mesenchymal tumor, with exclusive surgical treatment and excellent prognosis, although it may have malignant transformation. The reported case could represent the second case of AMFB with malignant transformation.

**Methodology** A 45-year-old woman with a 1 month history of painful vulvar mass of progressive growth. Physical examination reveals a stony, mobile mass of 5 × 5 cm in right labia majora. Initial immunostaining suggested an AMFB, so she was taken to vulvectomy. A review was made of all articles in English or Spanish, published until March 10, 2019, related to the diagnosis and treatment of vulvar AMFB. The search included the PubMed, Embase, Cochrane, LILACS and Scielo databases, with the keywords "Vulvar Angiomyofibroblastoma" OR "Angiomyofibroblastoma of the vulva with sarcomatous transformation".

**Results** A total of 69 reported cases were found. In our knowledge, the case presented is the first report of AMFB in Colombia. The age of the patients ranged between 16 and 82 years, with an average of 43 years. The main presenting symptom was the presence of a non-painful vulvar mass, although some of the patients in the reported cases reported pain and dyspareunia (8/69). The evolution time varied between 1 month and 9 years with an average of 21 months, and the size between 1 and 37 centimeters with an average of 7 centimeters. Of the cases taken to immunohistochemical study, 86% were positive for estrogen receptors and 80% for progesterone receptors, 88% were positive for desmin and 98% for vimentin, 92% were negative for S100 and the cases that were positive corresponded to the lipomatous variant, 43% were positive for α-SMA and 34% for CD 34. Definitive diagnosis is based on histological findings. In this reviewed cases, only one relapse was reported. The universal treatment is excision and only one case of relapse was reported, which corresponded to the only reported case of malignant transformation.
deprivation. Tumours with stage 1 disease at diagnosis were excluded from analysis of variation in treatment. Treatment variations across the 19 cancer alliances (units of geography) were evaluated. Survival analyses were extracted from a previous cohort diagnosed 2013–2017.

**Results**

Treatment received in 13,889 ovarian cancers was analysed. The weighted average probability (range for cancer alliances) of a stage 2–4 ovarian cancer receiving any treatment, any surgery, and any chemotherapy across England was 73.8% (70.4% - 79.3%), 51% (37.2% - 58.9%) and 66.5% (61.8% - 73.6%) respectively (figure 1). One-year net survival for the 19 Cancer Alliances in England varied between 62.9% and 75.2%, 5-year net survival varied between 28.6% and 49.6%. Cancer Alliances that were statistically less likely to undertake surgery generally had lower than average survival (figure 2).

**Conclusion**

Significant variation in treatment and survival across England are demonstrated in this audit. The population-based nature of this robust audit indicates that our findings are likely to be relevant to international settings. Efforts to understand and reduce variation in treatment decision making and reducing the proportion of women not receiving treatment are critical to improving survival in ovarian cancer. Ongoing audit of treatment will be key to driving and monitoring progress.

**Abstract 604 Figure 1**  Variation in treatment for women with advanced OC

Data from 13,889 women diagnosed between 2016–2018, figures from Treatment variation report of the National Ovarian Cancer Feasibility pilot audit

Fig 1A. Variation in receiving any anticancer treatment

Fig 1B. Variation in receiving surgery

Fig 1C. Variation in receiving chemotherapy

Outer Dashed lines indicate 3 standard deviations

**Abstract 604 Figure 2**  A) Variation across 19 Cancer Alliances in England for patients with advanced OC receiving surgery: women diagnosed 2016–2018

B) Survival analysis from 19 Cancer alliances in England women diagnosed 2013–2017

Interpretation - Stressing differences in the time coverage & cohort definitions, cross-referencing treatment variation & survival analyses suggests Cancer Alliances less likely to undertake surgery had generally lower than average five year survival